Sustainable release of carmustine from biodegradable poly[(d,l)-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies

Bibliography

• Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479‐89
   PubMed Web of Science ®Google Scholar
• Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep 2011;11:305‐12
   PubMed Web of Science ®Google Scholar
• Aoki T, Hashimoto N, Matsutani M. Management of glioblastoma. Expert Opin Pharmacother 2007;8:3133‐46
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114‐23
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000;2:45‐59
   PubMed Web of Science ®Google Scholar
• Black PM. Brain tumors. Part 1. N Engl J Med 1991;324:1471‐6
   PubMed Web of Science ®Google Scholar
• Mason WP, Cairncross JG. Drug insight: temozolomide as a treatment for malignant glioma–impact of a recent trial. Nat Clin Pract Neurol 2005;1:88‐95
   PubMedGoogle Scholar
• Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori 2008;94:271‐7
   PubMed Web of Science ®Google Scholar
• Degen JW, Walbridge S, Vortmeyer AO, et al. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 2003;99:893‐8
   PubMed Web of Science ®Google Scholar
• Jain KK. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 2012;7:1225‐33
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583‐8
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15:2887‐93
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269‐75
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44‐8
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79‐88
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008‐12
   PubMed Web of Science ®Google Scholar
• Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001;74:63‐7
   PubMed Web of Science ®Google Scholar
• Chen DW, Liao JY, Liu SJ, Chan EC. Novel biodegradable sandwich-structured nanofibrous drug-eluting membranes for repair of infected wounds: an in vitro and in vivo study. Int J Nanomedicine 2012;7:763‐71
   PubMed Web of Science ®Google Scholar
• Liu SJ, Kau YC, Liaw CW, Peng YJ. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs. Int J Pharm 2009;370:75‐80
   PubMedGoogle Scholar
• Bota DA, Desjardins A, Quinn JA, et al. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag 2007;3:707‐15
   PubMedGoogle Scholar
• Barbu E, Molnar E, Tsibouklis J, Gorecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2009;6:553‐65
   PubMed Web of Science ®Google Scholar
• Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw 2005;3:721‐8
   PubMedGoogle Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41:403‐19
   PubMed Web of Science ®Google Scholar
• Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987;21:607‐14
   PubMed Web of Science ®Google Scholar
• Sneed PK, Gutin PH, Larson DA, et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994;29:719‐27
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992;24:55‐7
   PubMed Web of Science ®Google Scholar
• Halperin EC, Burger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys 1988;15:505‐9
   PubMed Web of Science ®Google Scholar
• Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986;65:654‐8
   PubMed Web of Science ®Google Scholar
• Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003;24:3311‐31
   PubMed Web of Science ®Google Scholar
• Wu L, Ding J. In vitro degradation of three-dimensional porous poly(D,L-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2004;25:5821‐30
   PubMed Web of Science ®Google Scholar
• Mi FL, Lin YM, Wu YB, et al. Chitin/PLGA blend microspheres as a biodegradable drug-delivery system: phase-separation, degradation and release behavior. Biomaterials 2002;23:3257‐67
   PubMed Web of Science ®Google Scholar
• Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640‐7
   PubMed Web of Science ®Google Scholar
• Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol 2011;80:54‐68
   PubMed Web of Science ®Google Scholar
• Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007;28:4947‐67
   PubMed Web of Science ®Google Scholar
• Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108‐19
   PubMedGoogle Scholar
• Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 2007;7:363‐72
   PubMed Web of Science ®Google Scholar
• Xie H, Smith JW. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system. J Nanobiotechnology 2010;8:18
   PubMedGoogle Scholar
• Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 2009;26:235‐43
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanobiotechnology in the personalized management of glioblastoma multiforme. Nanomedicine (Lond) 2012;6:411‐14
   Web of Science ®Google Scholar